The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?

Massimo Puoti, Alessandro Cozzi-Lepri, Fausto Ancarani, Raffaele Bruno, Silvia Ambu, Teresa Ferraro, Paolo Tundo, Teresa Santantonio, Mario Toti, Marino Bonasso, Antonella D'Arminio Monforte

Research output: Contribution to journalArticlepeer-review

Abstract

We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HMRT) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [-81.1 mU/ml mean difference; 95% confidence intervals (95% CI): -30.3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07;95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen.

Original languageEnglish
Pages (from-to)811-817
Number of pages7
JournalAntiviral Therapy
Volume9
Issue number5
Publication statusPublished - Oct 2004

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?'. Together they form a unique fingerprint.

Cite this